View Older Stories View More Recent Stories
-
Mirum Pharmaceuticals to Present Phase 2 Clinical Results of Maralixibat in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis at the International Liver Congress
-
Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
-
Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
-
Mirum Pharmaceuticals Appoints Chris Peetz as Chief Executive Officer
-
Neos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
-
Harvard and Deerfield Establish Lab1636, a Major Translational Research Alliance
-
Harvard and Deerfield establish Lab1636, a major translational research alliance
-
TriNetX Secures $40 Million in Series D Funding
-
Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator
-
Nuvo Pharmaceuticals™ Announces Receipt of Shareholder Approval By Way of Written Consent For the Issuance of Common Shares Pursuant to Convertible Notes and Warrants
-
Itamar Medical to Commence Trading on Nasdaq
-
Deerfield and Oxeon Join Forces with HLTH to Connect Healthcare Leaders with Qualified Female Board Candidates
-
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
-
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
-
Melinta Therapeutics (MLNT) Board Approves 1-for-5 Reverse Stock Split
-
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
-
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Adeptus Health Appoints James Hopwood as its Chief Financial Officer
-
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
-
Deerfield Management Advanced Healthcare Initiatives Globally Through Academic Collaborations, Publications, and Philanthropy
-
CathWorks Announces Completion of $30 Million Financing
-
Melinta Therapeutics (MLNT) Provides Updates on Strategic Repositioning Initiatives, Cost Savings Outlook
-
Melinta Therapeutics Provides Corporate Updates
-
Melinta Therapeutics Provides Corporate Updates
-
Itamar Medical Announces Definitive Agreements for $11.5 Million Private Placement
-
FTI Consulting’s Corporate Finance & Restructuring Segment Wins Several Industry Awards
-
FTI Consulting’s Corporate Finance & Restructuring Segment Wins Several Industry Awards
-
Johnson & Johnson Innovation to Join NXT Biomedical Therapeutic Device Incubator to Accelerate Medical Device Innovation
-
PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease
-
Stelexis Therapeutics Closes $43 million Series A to Expand Novel Platform Focused on Cancer Interception
-
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer
-
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cel
-
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cel
-
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
-
Nuvo Pharmaceuticals™ to Host Conference Call/Audio Webcast to Discuss the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
-
Nuvo Pharmaceuticals™ Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
-
ARS Pharmaceuticals Advances Clinical Program for Intranasal Epinephrine Spray
-
Nuvo Pharmaceuticals™ Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
-
Aralez Pharmaceuticals to Seek Court Approval of Previously Announced "Stalking Horse" Transactions for Substantially All Assets
-
Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications
-
SHINE And Deerfield Close $150 Million Financing Commitment To Support Diagnostic And Therapeutic Medical Isotope Manufacturing
-
Form 13F-HR DEERFIELD MANAGEMENT For: Sep 30
-
Citco Launches New SaaS Æxeo Treasury™ Solution on Amazon Web Services
-
Dana-Farber Cancer Institute and Deerfield Collaborate to Create the Center for Protein Degradation
-
Citco Launches New SaaS Æxeo Treasury™ Solution on Amazon Web Services
-
Neos Therapeutics Reports Third Quarter 2018 Financial Results
-
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
-
Nuvo Pharmaceuticals™ Announces 2018 Third Quarter Results
-
Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases

